Back to Search
Start Over
Identification of Prostate-Specific G-Protein Coupled Receptor as a Tumor Antigen Recognized by CD8+ T Cells for Cancer Immunotherapy.
- Source :
- PLoS ONE; Sep2012, Vol. 7 Issue 9, Special section p1-9, 9p
- Publication Year :
- 2012
-
Abstract
- Background: Prostate cancer is the most common cancer among elderly men in the US, and immunotherapy has been shown to be a promising strategy to treat patients with metastatic castration-resistant prostate cancer. Efforts to identify novel prostate specific tumor antigens will facilitate the development of effective cancer vaccines against prostate cancer. Prostate-specific G-protein coupled receptor (PSGR) is a novel antigen that has been shown to be specifically over-expressed in human prostate cancer tissues. In this study, we describe the identification of PSGR-derived peptide epitopes recognized by CD8<superscript>+</superscript> T cells in an HLA-A2 dependent manner. Methodology/Principal Findings: Twenty-one PSGR-derived peptides were predicted by an immuno-informatics approach based on the HLA-A2<superscript>+</superscript> binding motif. These peptides were examined for their ability to induce peptide-specific T cell responses in peripheral blood mononuclear cells (PBMCs) obtained from either HLA-A2<superscript>+</superscript> healthy donors or HLA- A2<superscript>+</superscript> prostate cancer patients. The recognition of HLA-A2 positive and PSGR expressing LNCaP cells was also tested. Among the 21 PSGR-derived peptides, three peptides, PSGR3, PSGR4 and PSGR14 frequently induced peptide-specific T cell responses in PBMCs from both healthy donors and prostate cancer patients. Importantly, these peptide-specific T cells recognized and killed LNCaP prostate cancer cells in an HLA class I-restricted manner. Conclusions/Significance: We have identified three novel HLA-A2-restricted PSGR-derived peptides recognized by CD8<superscript>+</superscript> T cells, which, in turn, recognize HLA-A2<superscript>+</superscript> and PSGR<superscript>+</superscript> tumor cells. The PSGR-derived peptides identified may be used as diagnostic markers as well as immune targets for development of anticancer vaccines. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 19326203
- Volume :
- 7
- Issue :
- 9
- Database :
- Complementary Index
- Journal :
- PLoS ONE
- Publication Type :
- Academic Journal
- Accession number :
- 82447525
- Full Text :
- https://doi.org/10.1371/journal.pone.0045756